Tonix Pharmaceuticals Holding Corp. (TNXP) DCF Valuation

Tonix Pharmaceuticals Holding Corp. (TNXP) DCF Valuation
  • ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
  • ✓ Professional Design: Trusted, Industry-Standard Templates
  • ✓ Pre-Built For Quick And Efficient Use
  • ✓ No Expertise Is Needed; Easy To Follow

Tonix Pharmaceuticals Holding Corp. (TNXP) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our (TNXP) DCF Calculator enables you to evaluate Tonix Pharmaceuticals Holding Corp. valuation using real-world financial data and offers complete flexibility to modify all essential parameters for improved projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 7.8 7.8 7.8 7.8 7.8 7.8
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -28.8 -50.5 -92.3 -110.8 -114.1 4.7 4.7 4.7 4.7 4.7
EBITDA, % 100 100 100 100 -1468.7 60 60 60 60 60
Depreciation .0 .0 .1 1.3 4.3 7.1 7.1 7.1 7.1 7.1
Depreciation, % 100 100 100 100 55.24 91.05 91.05 91.05 91.05 91.05
EBIT -28.8 -50.5 -92.3 -112.1 -118.4 4.7 4.7 4.7 4.7 4.7
EBIT, % 100 100 100 100 -1523.94 60 60 60 60 60
Total Cash 11.2 77.1 178.7 120.2 24.9 7.8 7.8 7.8 7.8 7.8
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 7.6 7.7 .0 4.6
Account Receivables, % 100 100 100 100 59.09
Inventories -1.0 -7.6 -7.7 -8.0 14.1 7.8 7.8 7.8 7.8 7.8
Inventories, % 100 100 100 100 182.12 100 100 100 100 100
Accounts Payable 3.1 4.6 13.3 8.1 3.8 7.0 7.0 7.0 7.0 7.0
Accounts Payable, % 100 100 100 100 48.69 89.74 89.74 89.74 89.74 89.74
Capital Expenditure .0 -8.6 -35.3 -48.1 -7.9 -1.6 -1.6 -1.6 -1.6 -1.6
Capital Expenditure, % 100 100 100 100 -101.63 -20 -20 -20 -20 -20
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -31.3 -52.2 -92.3 -118.9 -118.4 4.7 4.7 4.7 4.7 4.7
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -27.2 -60.2 -118.9 -162.9 -153.1 17.2 10.2 10.2 10.2 10.2
WACC, % 4.63 4.63 4.63 4.63 4.63 4.63 4.63 4.63 4.63 4.63
PV UFCF
SUM PV UFCF 51.2
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 10
Terminal Value 395
Present Terminal Value 315
Enterprise Value 367
Net Debt -15
Equity Value 382
Diluted Shares Outstanding, MM 1
Equity Value Per Share 716.88

What You Will Get

  • Real TNXP Financial Data: Pre-filled with Tonix Pharmaceuticals’ historical and projected data for precise analysis.
  • Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
  • Automatic Calculations: See Tonix Pharmaceuticals’ intrinsic value update instantly based on your changes.
  • Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
  • User-Friendly Design: Simple structure and clear instructions for all experience levels.

Key Features

  • Comprehensive TNXP Data: Pre-filled with Tonix Pharmaceuticals' historical financials and future projections.
  • Fully Adjustable Inputs: Modify revenue growth, profit margins, WACC, tax rates, and capital expenditures as needed.
  • Dynamic Valuation Model: Instant updates to Net Present Value (NPV) and intrinsic value based on your customized inputs.
  • Scenario Analysis: Develop various forecast scenarios to explore different valuation possibilities.
  • User-Friendly Interface: Intuitive, organized, and suitable for both professionals and novices.

How It Works

  • Step 1: Download the prebuilt Excel template featuring Tonix Pharmaceuticals' data.
  • Step 2: Navigate through the pre-filled sheets to grasp the essential metrics.
  • Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view recalculated results, including Tonix Pharmaceuticals' intrinsic value.
  • Step 5: Make informed investment decisions or create reports based on the outputs.

Why Choose This Calculator for Tonix Pharmaceuticals (TNXP)?

  • Designed for Industry Experts: A sophisticated tool favored by analysts, CFOs, and healthcare consultants.
  • Accurate Financial Data: Tonix Pharmaceuticals' historical and projected financials preloaded for precision.
  • Comprehensive Scenario Analysis: Effortlessly simulate various forecasts and assumptions.
  • Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
  • User-Friendly Interface: Step-by-step guidance to navigate through the calculation process.

Who Should Use Tonix Pharmaceuticals Holding Corp. (TNXP)?

  • Investors: Gain insights into the pharmaceutical sector with a reliable research platform.
  • Financial Analysts: Streamline your analysis with comprehensive data on TNXP's market performance.
  • Consultants: Easily modify reports and presentations to showcase TNXP's potential to clients.
  • Pharmaceutical Enthusiasts: Enhance your knowledge of drug development and market trends through TNXP's case studies.
  • Educators and Students: Utilize it as a resource for learning about the pharmaceutical industry and investment strategies.

What the Template Contains

  • Historical Data: Includes Tonix Pharmaceuticals' past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate Tonix Pharmaceuticals' intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of Tonix Pharmaceuticals' financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.